Literature DB >> 19735056

Beneficial effects of N-acetylcysteine in treatment resistant schizophrenia.

Mahmut Bulut1, Haluk Asuman Savas, Abdurrahman Altindag, Osman Virit, Alican Dalkilic.   

Abstract

Poor response to antipsychotics is still an important problem in the treatment of many schizophrenia patients. N-acetylcysteine (NAC) is a compound that exerts anti-oxidant and scavenging actions against reactive oxygen species. This paper reports a case of poorly responsive schizophrenia patient who improved considerably with add-on NAC 600 mg/day. The NAC might work through activating cysteine-glutamate antiporters or reducing in nitric oxide (NO) metabolites, free radicals and cytokines or through both of these mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735056     DOI: 10.1080/15622970903144004

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  24 in total

Review 1.  Targeting Oxidative Stress and Aberrant Critical Period Plasticity in the Developmental Trajectory to Schizophrenia.

Authors:  Kim Q Do; Michel Cuenod; Takao K Hensch
Journal:  Schizophr Bull       Date:  2015-06-01       Impact factor: 9.306

2.  Oxidative/Nitrosative stress in psychiatric disorders: are we there yet?

Authors:  Patricio O'Donnell; Kim Q Do; Celso Arango
Journal:  Schizophr Bull       Date:  2014-04-08       Impact factor: 9.306

Review 3.  N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review.

Authors:  Adam Daniel Zavodnick; Rizwan Ali
Journal:  Psychiatr Q       Date:  2014-06

Review 4.  N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.

Authors:  Olivia Dean; Frank Giorlando; Michael Berk
Journal:  J Psychiatry Neurosci       Date:  2011-03       Impact factor: 6.186

Review 5.  Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (System xc-) to normal and pathological glutamatergic signaling.

Authors:  Richard Bridges; Victoria Lutgen; Doug Lobner; David A Baker
Journal:  Pharmacol Rev       Date:  2012-07       Impact factor: 25.468

6.  Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress.

Authors:  Marilena Colaianna; Stefania Schiavone; Margherita Zotti; Paolo Tucci; Maria Grazia Morgese; Liselotte Bäckdahl; Rikard Holmdahl; Karl-Heinz Krause; Vincenzo Cuomo; Luigia Trabace
Journal:  Antioxid Redox Signal       Date:  2013-04-20       Impact factor: 8.401

Review 7.  NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.

Authors:  Becky A Diebold; Susan M E Smith; Yang Li; J David Lambeth
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 8.  Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

Authors:  P Steullet; J H Cabungcal; A Monin; D Dwir; P O'Donnell; M Cuenod; K Q Do
Journal:  Schizophr Res       Date:  2014-07-05       Impact factor: 4.939

Review 9.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

Review 10.  Effect of N-acetyl cysteine (NAC) supplementation on positive and negative syndrome scale in schizophrenia: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Amir Ghaderi; Anna Bussu; Catherine Tsang; Sadegh Jafarnejad
Journal:  Eur J Clin Pharmacol       Date:  2018-11-16       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.